The Oncology Institute, Inc. (NASDAQ:TOI) Sees Significant Decrease in Short Interest

The Oncology Institute, Inc. (NASDAQ:TOI) saw a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 173,500 shares, a decrease of 86.0% from the November 30th total of 1,240,000 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily volume of 1,640,000 shares, the short-interest ratio is presently 0.1 days.

Insider Buying and Selling at Oncology Institute

In other Oncology Institute news, Director Brad Hively purchased 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was purchased at an average price of $0.17 per share, for a total transaction of $42,500.00. Following the purchase, the director now directly owns 616,753 shares in the company, valued at approximately $104,848.01. This trade represents a 68.17 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.50% of the company’s stock.

Institutional Trading of Oncology Institute

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tiff Advisory Services LLC boosted its position in shares of Oncology Institute by 235.1% in the second quarter. Tiff Advisory Services LLC now owns 1,418,685 shares of the company’s stock worth $653,000 after acquiring an additional 995,280 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Oncology Institute by 142.3% in the 2nd quarter. Renaissance Technologies LLC now owns 339,400 shares of the company’s stock valued at $156,000 after purchasing an additional 199,300 shares during the last quarter. Finally, HighTower Advisors LLC increased its holdings in shares of Oncology Institute by 190.8% during the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock worth $27,000 after buying an additional 53,382 shares during the last quarter. 36.86% of the stock is owned by hedge funds and other institutional investors.

Oncology Institute Price Performance

Shares of TOI stock traded up $0.05 during trading hours on Friday, hitting $0.32. The company’s stock had a trading volume of 1,221,846 shares, compared to its average volume of 544,142. The business has a fifty day moving average of $0.24 and a 200-day moving average of $0.35. The stock has a market cap of $23.91 million, a price-to-earnings ratio of -0.41 and a beta of 0.43. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 5.91. Oncology Institute has a twelve month low of $0.13 and a twelve month high of $2.50.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.